Petri Vainio joined EW in 2004 as Managing Director, leads the EW growth equity investment practice, and serves as the Chairman of the Firm’s Executive Committee.
Dr. Vainio has 30 years of experience as an investor in rapidly growing healthcare companies. He has invested in and served on the board of over 20 rapidly growing healthcare companies which have raised over $1 billion in private growth capital and reached a total market capitalization of over $60 billion. He has led several EW growth equity investments including Biotoscana (acquired by Knight Therapeutics), EUSA Pharma (acquired by Jazz Pharmaceuticals) and Healthcare Brands International (acquired by Meda Pharmaceuticals). Dr. Vainio currently serves on the Board of Directors of EW portfolio companies EUSA Pharma and Molecular Partners.
Prior to joining EW, Dr. Vainio spent 12 years as a General Partner of Sierra Ventures, one of Silicon Valley’s venture capital firms with over $1 billion under management. While at Sierra, Dr. Vainio served as General Partner of five successive funds and led the firm’s healthcare investment practice.
Dr. Vainio holds a Doctor of Medicine and a Doctor of Philosophy from the University of Helsinki, and a Master in Business Administration from Stanford University.